Moderna Inc is a biotechnology business based in the US. Moderna shares (MRNA.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $99.99 – a decrease of 0.24% over the previous day. Moderna employs 3,900 staff and has a market cap (total outstanding shares value) of $38.1 billion.
How to buy shares in Moderna
Choose a platform.If you're a beginner, our stock-dealing table below can help you choose.
Open your account.Provide your personal information and sign up.
Confirm your payment details.You'll need to fund your account with a bank transfer, debit card or credit card.
Search the platform for stock code:MRNA in this case.
Research stocks.The platform should provide the latest information available.
Buy your stocks.It's that simple.
The whole process can take as little as 15 minutes. You'll need a smartphone or computer, an internet connection, your passport or driving licence and a means of payment.
Our selection of top picks is based on the same criteria as our annual Stock Trading Platform Awards. This is updated yearly to reflect changes in the market.
"Best for" picks are those we've evaluated to be best for specific product features or categories – you can read our full methodology here. If we show a "Promoted" pick, it's been chosen from among our commercial partners and is based on factors that include special features or offers, and the commission we receive.
This isn't an exhaustive list of all the trading platforms out there. What's best for you depends on your own investing strategy, budget and financial goals.
Latest updates for Moderna
August 18, 2023: Moderna announced positive results for its updated COVID vaccine and the stock price has responded positively.
Is it a good time to buy Moderna stock?
Only you can make the decision on the time to leap. The gauge below shows real-time ratings that are based on 26 popular indicators such as moving averages, for specific time periods. It's not a recommendation but is simply technical analysis that can form part of your research.
Finder might not agree with the analysis and we take no responsibility. We also give no representations or warranty on the accuracy or completeness of the information provided on this page.
Moderna stock price (NASDAQ:MRNA)
Use our graph to track the performance of MRNA stocks over time.
Share price volatility
Over the last 12 months, Moderna's shares have ranged in value from as little as $95.02 up to $217.25. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Moderna's is 1.6217. This would suggest that Moderna's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Historical closes compared with the last close of 99.99
1 week (2023-09-15)
-12.74%
1 month (2023-08-24)
-11.24%
3 months (2023-06-23)
-15.62%
6 months (2023-03-24)
-33.73%
1 year (2022-09-23)
-19.13%
2 years (2021-09-24)
-76.75%
3 years (2020-09-24)
53.43%
Buy Moderna stocks from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.
Note: The dollar amounts in the table below are in Canadian dollars.
1 - 4 of 4
Is Moderna stock undervalued or overvalued?
Valuing Moderna stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Moderna's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Moderna's P/E ratio
Moderna's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 35x. In other words, Moderna shares trade at around 35x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Moderna's EBITDA
Moderna's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $876 million.
The EBITDA is a measure of a Moderna's overall financial performance and is widely used to measure a its profitability.
Moderna financials
Revenue TTM
$10.7 billion
Operating margin TTM
4.82%
Gross profit TTM
$10.6 billion
Return on assets TTM
1.34%
Return on equity TTM
6.91%
Profit margin
11.33%
Book value
$44.49
Market capitalisation
$38.1 billion
TTM: trailing 12 months
Moderna share dividends
We're not expecting Moderna to pay a dividend over the next 12 months.
Moderna overview
Moderna, Inc. , a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella-zoster virus, and human immunodeficiency virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S. p. A.
Frequently asked questions
Currently 9.685% of Moderna stocks are held by insiders and 69.48% by institutions.
Latest data suggests 3,900 work at Moderna.
Moderna's fiscal year ends in December.
Moderna's address is: 200 Technology Square, Cambridge, MA, United States, 02139
Moderna's international securities identification number is: US60770K1079
Moderna's Committee on Uniform Securities Identification Procedures number is: 60770K107
Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.
Steps to owning and managing VICI with 24-hour and historical pricing before you buy.
Feedback
How likely would you be to recommend finder to a friend or colleague?
0
1
2
3
4
5
6
7
8
9
10
Very UnlikelyExtremely Likely
Required
Thank you for your feedback.
Our goal is to create the best possible product, and your thoughts, ideas and suggestions play a major role in helping us identify opportunities to improve.
Advertiser Disclosure
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.
Finder Award
